IntelGenx Grants Stock Options
March 27 2019 - 5:01PM
IntelGenx Technologies Corp. ("IntelGenx", or the “Company”)
(TSX-V: IGX) (OTC.QX:IGXT) announced today that the Company’s board
of directors granted 100,000 options to acquire 100,000 common
shares under the 2016 Stock Option Plan to Rodolphe Obeid, VP
Operations of IntelGenx Corp.
The options have an exercise price of US$0.69
(CAD$0.92), vest over a period of two years at the rate of 25%
every six months and expire on March 26, 2029.About
IntelGenx:
Established in 2003, IntelGenx is a leading oral
drug delivery company primarily focused on the development and
manufacturing of innovative pharmaceutical oral films based on its
proprietary VersaFilm™ technology platform.
IntelGenx' highly skilled team provides
comprehensive pharmaceuticals services to pharmaceutical partners,
including R&D, analytical method development, clinical
monitoring, IP and regulatory services. IntelGenx'
state-of-the-art manufacturing facility, established for the
VersaFilm™ technology platform, supports lab-scale to pilot and
commercial-scale production, offering full service capabilities to
its clients. More information about the Company can be found at
www.intelgenx.com.
Neither TSX Venture Exchange nor its Regulation
Services Provider (as that term is defined in the policies of the
TSX Venture Exchange), nor the OTCQX accepts responsibility for the
adequacy or accuracy of this release.
Contact:IntelGenx Technologies Corp.Ingrid
ZerbeCorporate Secretary514-331-7440
ingrid@intelgenx.com www.intelgenx.com
Intelgenx Technologies (TSXV:IGX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Intelgenx Technologies (TSXV:IGX)
Historical Stock Chart
From Apr 2023 to Apr 2024